KalVista Pharmaceuticals Acquired by Chiesi | Healthcare M&A Deal

Chiesi has acquired KalVista Pharmaceuticals, a pharmacy business in the United States, for $1.9 billion. Chiesi acquisitions add Ekterly, an oral on-demand hereditary angioedema treatment, to expand its rare disease portfolio and U.S. commercial footprint. KalVista Pharmaceuticals develops therapies for hereditary angioedema, a genetic swelling disorder historically treated with injectable on-demand and preventive options. The platform acquisition is a strategic acquisition by the family-owned Italian drugmaker, valued at $1.9B, to strengthen its rare disease unit and support 2030 revenue targets, with the deal announced and subject to customary closing conditions.